Share on LinkedInShare on LinkedIn

ARTICLE · 15 NOVEMBER 2023

My Prescription Costs What?

Axinn
Axinn
Contributor
Axinn

Axinn

Incisive. Inclusive. Invested. We’re Axinn. Experienced, tenacious, and always trial-ready, we are...

View firm profile
Explore more from Axinn

This WSJ story highlights the challenges faced by patients as they navigate the "convoluted" ways in which drug prices are set between manufacturers and the pharmacy benefit managers (PBMs)...

United StatesAntitrust/Competition Law

This WSJ story highlights the challenges faced by patients as they navigate the "convoluted" ways in which drug prices are set between manufacturers and the pharmacy benefit managers (PBMs) who negotiate on behalf of health insurance plans.

As featured in the WSJ story, patients can find two dramatically different prices for the same drug – one price using their insurance benefits, and another by paying cash out of pocket. These types of "funky" results arising from the complexities of the US healthcare payer system are also gaining the attention of legislators, policy organizations -- and antitrust enforcers. In June 2022, the FTC launched a market study of PBMs and the impact of their practices on pharmacies, payers, doctors, and patients.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from